SG11201702056YA - Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition - Google Patents
Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibitionInfo
- Publication number
- SG11201702056YA SG11201702056YA SG11201702056YA SG11201702056YA SG11201702056YA SG 11201702056Y A SG11201702056Y A SG 11201702056YA SG 11201702056Y A SG11201702056Y A SG 11201702056YA SG 11201702056Y A SG11201702056Y A SG 11201702056YA SG 11201702056Y A SG11201702056Y A SG 11201702056YA
- Authority
- SG
- Singapore
- Prior art keywords
- mediating
- treatment
- hiv
- monoclonal antibodies
- competitive
- Prior art date
Links
- 208000031886 HIV Infections Diseases 0.000 title 1
- 208000037357 HIV infectious disease Diseases 0.000 title 1
- 230000002860 competitive effect Effects 0.000 title 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051200P | 2014-09-16 | 2014-09-16 | |
| PCT/US2014/065048 WO2016043788A1 (en) | 2014-09-16 | 2014-11-11 | Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201702056YA true SG11201702056YA (en) | 2017-04-27 |
Family
ID=55533661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201702056YA SG11201702056YA (en) | 2014-09-16 | 2014-11-11 | Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition |
Country Status (14)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019001814A (es) * | 2016-08-13 | 2019-07-08 | Ubi Ip Holdings | Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart. |
| EP3762014A4 (en) * | 2018-03-05 | 2021-08-25 | Oncoimmune, Inc. | METHODS OF USING SOLUBLE CD24 FOR THE TREATMENT OF ACQUIRED IMMUNODEFICIENCY SYNDROME (HIV / AIDS) |
| EP4090348A4 (en) * | 2020-01-13 | 2024-05-15 | The Regents of The University of California | METHODS FOR TREATING VIRAL INFECTIONS |
| CN116063506A (zh) * | 2022-09-02 | 2023-05-05 | 华道(上海)生物医药有限公司 | 一种分离的抗体及其用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4381295A (en) | 1979-04-26 | 1983-04-26 | Ortho Pharmaceutical Corporation | Monoclonal antibody to human helper T cells and methods of preparing same |
| DE3828582A1 (de) | 1988-08-23 | 1990-03-01 | Max Planck Gesellschaft | Monoklonaler antikoerper zur inhibierung der infektion von zellen durch hiv-viren |
| EP0365209A3 (en) | 1988-10-17 | 1990-07-25 | Becton, Dickinson and Company | Anti-leu 3a amino acid sequence |
| JPH0725794B2 (ja) | 1990-03-23 | 1995-03-22 | 呉羽化学工業株式会社 | 新規なペプチド |
| EP0512112B1 (en) | 1990-11-27 | 1997-05-28 | Biogen, Inc. | Anti cd-4 antibodies blocking hiv-induced syncytia |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| JPH06125783A (ja) | 1991-12-28 | 1994-05-10 | Chemo Sero Therapeut Res Inst | 組換え抗ｈｉｖ抗体およびその調製方法 |
| DK0746613T3 (da) | 1994-03-08 | 2006-09-25 | Sloan Kettering Inst Cancer | Rekombinante humaniserede antistoffer mod FB5 |
| US5961976A (en) | 1996-06-03 | 1999-10-05 | United Biomedical, Inc. | Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV |
| JP3231262B2 (ja) | 1996-06-05 | 2001-11-19 | 株式会社ビー・エム・エル | ヒトＴｈ１特異的タンパク質及びこれをコードする遺伝子、並びにこれに関連する形質転換体、組換えベクター及び抗体 |
| US5962319A (en) | 1997-05-19 | 1999-10-05 | Bml, Inc. | Human-Th1-specific protein, gene encoding the protein, transformants, recombinant vectors, and antibodies related to the gene |
| JPH10155489A (ja) | 1996-11-27 | 1998-06-16 | Asahi Chem Ind Co Ltd | 組換え抗体及びそれをコードする核酸 |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| US6051228A (en) * | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| CN1307640A (zh) | 1998-05-25 | 2001-08-08 | 旭化成株式会社 | 细胞分离装置和分离方法 |
| US6090388A (en) | 1998-06-20 | 2000-07-18 | United Biomedical Inc. | Peptide composition for prevention and treatment of HIV infection and immune disorders |
| AR029337A1 (es) * | 1999-03-02 | 2003-06-25 | Schering Corp | Uso de interferon alfa pegilado para la preparacion de un medicamento para la terapia contra el hiv |
| EP1454137B1 (de) * | 2001-12-11 | 2008-02-13 | BIOTECTID GmbH | Verwendung eines markierten liganden mit spezifität für das humane cd4-molekül |
| JP2003327536A (ja) | 2002-03-07 | 2003-11-19 | Kitasato Inst:The | ヒト免疫不全症候群ウイルスの感染、増殖抑制剤 |
| US20030211470A1 (en) * | 2002-03-15 | 2003-11-13 | Olson William C. | CD4-IgG2-based salvage therapy of HIV-1 infection |
| US7501494B2 (en) | 2003-01-15 | 2009-03-10 | United Biomedical, Inc. | Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection |
| KR100633856B1 (ko) * | 2005-07-08 | 2006-10-13 | 조통래 | 산소와 오존을 함유한 미세기포가 녹아 있는 작물의병해충방제제 |
| WO2007094983A2 (en) * | 2006-02-03 | 2007-08-23 | Tanox, Inc. | Methods and compositions for the inhibition of hiv infection of t cells |
| US20130195881A1 (en) * | 2007-04-27 | 2013-08-01 | Sanjaya Singh | Potent, stable and non-immunosuppressive anti-cd4 antibodies |
-
2014
- 2014-11-11 MX MX2017003546A patent/MX2017003546A/es unknown
- 2014-11-11 WO PCT/US2014/065048 patent/WO2016043788A1/en active Application Filing
- 2014-11-11 JP JP2017514874A patent/JP6716544B2/ja active Active
- 2014-11-11 EP EP14902149.5A patent/EP3194442A4/en not_active Ceased
- 2014-11-11 CA CA2961464A patent/CA2961464A1/en active Pending
- 2014-11-11 CN CN201480081992.3A patent/CN107074944A/zh active Pending
- 2014-11-11 US US15/512,043 patent/US11180555B2/en active Active
- 2014-11-11 SG SG11201702056YA patent/SG11201702056YA/en unknown
- 2014-11-11 AU AU2014406462A patent/AU2014406462A1/en not_active Abandoned
- 2014-11-11 BR BR112017005134A patent/BR112017005134A2/pt not_active IP Right Cessation
- 2014-11-11 RU RU2017112967A patent/RU2762315C2/ru not_active Application Discontinuation
- 2014-11-11 KR KR1020177009857A patent/KR20170054478A/ko not_active Ceased
-
2015
- 2015-09-16 TW TW104130548A patent/TWI695720B/zh active
-
2017
- 2017-03-15 ZA ZA2017/01856A patent/ZA201701856B/en unknown
-
2019
- 2019-11-01 JP JP2019199493A patent/JP2020097569A/ja active Pending
-
2021
- 2021-05-13 AU AU2021203071A patent/AU2021203071B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170054478A (ko) | 2017-05-17 |
| EP3194442A1 (en) | 2017-07-26 |
| JP2020097569A (ja) | 2020-06-25 |
| RU2762315C2 (ru) | 2021-12-17 |
| US11180555B2 (en) | 2021-11-23 |
| ZA201701856B (en) | 2020-08-26 |
| CA2961464A1 (en) | 2016-03-24 |
| US20170369576A1 (en) | 2017-12-28 |
| RU2017112967A (ru) | 2018-10-17 |
| MX2017003546A (es) | 2017-08-14 |
| CN107074944A (zh) | 2017-08-18 |
| BR112017005134A2 (pt) | 2017-12-12 |
| EP3194442A4 (en) | 2018-05-23 |
| JP6716544B2 (ja) | 2020-07-01 |
| AU2021203071A1 (en) | 2021-06-17 |
| AU2021203071B2 (en) | 2024-11-21 |
| WO2016043788A1 (en) | 2016-03-24 |
| RU2017112967A3 (enrdf_load_stackoverflow) | 2018-10-17 |
| JP2017529355A (ja) | 2017-10-05 |
| TW201611845A (en) | 2016-04-01 |
| AU2014406462A1 (en) | 2017-04-06 |
| TWI695720B (zh) | 2020-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202102219B (en) | Dosage and administration of non-fucosylated anti-cd40 antibodies | |
| IL267798B (en) | Human antibodies to pd-1 | |
| ZA201706155B (en) | Neutralizing antibodies to gp120 and their use | |
| SI3347352T1 (sl) | Terapevtske spojine uporabne za profilaktično ali terapevtsko zdravljenje okužbe z virusom HIV | |
| IL252680A0 (en) | A combination of Listeria-based vaccine and antibodies against tumor necrosis factor receptor 4 or 18 | |
| IL245436A0 (en) | New dihydroquinolizinones for the treatment and prevention of hepatitis b virus infection | |
| SG11201609652RA (en) | Treatment of polybacterials infections | |
| PT3182996T (pt) | Métodos de tratamento de mieloma múltiplo com compostos imunomoduladores em combinação com anticorpos | |
| GB201618424D0 (en) | Treatment of antibody mediated disease | |
| DK3250600T3 (da) | Behandling af autoimmune lidelser med cd154-antistoffer | |
| IL252535A0 (en) | A combination of cs1 and pd1 antibodies for the treatment of cancer (myeloma) | |
| IL320757A (en) | Treating hand eczema | |
| ZA201701856B (en) | Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition | |
| DK2991664T3 (da) | Midler til forebyggelse og behandling af følgesygdomme af HIV og andre virusinfektioner | |
| HK1236541A1 (en) | Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition | |
| HK1236541A (en) | Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition | |
| GB201400005D0 (en) | Treatment of auto immune diseases useing monocloani antibodies | |
| TH1501005991A (th) | แมโครไซคลิก ดีเอซา-พิวริโนน เพื่อบำบัดการติดเชื้อไวรัส | |
| TH1601001266A (th) | วิธีการและองค์ประกอบทางเภสัชกรรมสำหรับการบำบัดการติดเชื้อไวรัสตับอักเสบ b |